Menu
Oncology Evolved
Engineering the Next Generation of Off-the-Shelf Cell Therapies
PIPELINE
PRE-CLINICAL
CLINICAL
CAR-T (Allogeneic)
T-ALL/LBL
WU-CART-007
Memory NK (Allogeneic)
AML
WU-NK-101
Solid Tumors
WU-NK-101 + mAb
Solid Tumors
WU-NK-201 Engineered
LATEST NEWS
Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium
-- WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors -- --WU-NK-101 exhibited robust trafficking, intra-tumor infiltration,…
Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting
-- Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell…
Wugen to Present at the Upcoming Jefferies London Healthcare Conference
SAINT LOUIS, MO and SAN DIEGO, CA, November 10, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…
Copyright © 2022 Wugen. All Rights Reserved.
a COGNEO design